← Eichor
Study identifier: NCT06841159 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer

Condition: Microsatellite Stable Metastatic Colorectal Cancer  ·  Sponsor: Fudan University

PhasePhase 2
Planned participants116
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

To improve the survival in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) by loco-regional therapy with personalized ultra-fractionated radiation plus immunotherpy.

This description comes directly from the study's public registry record.

Talk to the study team

Zhen Zhang, MD,PhD  ·  86-0204256577200  ·  zhen_zhang@fudan.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Fudan UniversityShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06841159